Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3023% above fair value
$3.13−0.14 (-4.28%)
Close on Nov 13, 2026Market cap $73.42MP/E –Yield –
Coya Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Coya Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -643.5%. For fiscal 2025 it was -267.1%, against -418.7% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -267.1% | +151.6 |
| FY2024 | Dec 31, 2024 | -418.7% | −285.6 |
| FY2023 | Dec 31, 2023 | -133.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -4534.9% | −4475.5 |
| Q2 FY2026 | Jun 30, 2026 | -2723.4% | +1001.7 |
| Q1 FY2026 | Mar 31, 2026 | -2869.6% | −36.3 |
| Q4 FY2025 | Dec 31, 2025 | -144.2% | +149229.6 |
| Q3 FY2025 | Sep 30, 2025 | -59.4% | +25.1 |
| Q2 FY2025 | Jun 30, 2025 | -3725.2% | +257.8 |
| Q1 FY2025 | Mar 31, 2025 | -2833.4% | −2854.4 |
| Q4 FY2024 | Dec 31, 2024 | -149373.8% | – |
| Q2 FY2024 | Jun 30, 2024 | -84.4% | – |
| Q1 FY2024 | Mar 31, 2024 | -3983.0% | – |
| Q4 FY2023 | Dec 31, 2023 | 21.1% | – |
See a number that looks wrong?